Business Insights
Diagnostic Technologies
Diseases
Point-of-Care Testing
Research & Development
Sign In
About Us
Careers
Videos
Webinars
Press Releases
Whitepapers
Advertising
Payor Coverage: Page 2
Aspira Women’s Health announces milestones for expanded access to ovarian cancer risk test
By
LabPulse.com staff writers
The 2023 Omnibus Spending Bill contains language directing CMS to cover multimarker tests for ovarian cancer, increasing access to this testing; the expansion could encourage commercial insurers to adopt similar coverage policies.
December 27, 2022
Medicare policy increases access to noninvasive colorectal cancer tests: Exact Sciences
By
LabPulse.com staff writers
CMS is expanding coverage for certain colorectal cancer screening tests by reducing the minimum age payment and coverage limitation from 50 to 45 years.
December 20, 2022
Biodesix nabs positive coverage decisions from four private payors
By
LabPulse.com staff writers
The firm’s Nodify XL2 test will now be covered for enrollees of Blue Cross of North Carolina, Blue Cross Blue Shield of South Carolina, Blue Cross Blue Shield of Kansas City, and Capital District Physician’s Health Plan (CDPHP) of New York.
December 19, 2022
Cleveland Diagnostics nabs Medicare coverage for test that interrogates PSA structural variants
By
LabPulse.com staff writers
In large, prospective multicenter studies of men scheduled for biopsy, IsoPSA demonstrated greater diagnostic accuracy than PSA alone in identifying patients with high-grade cancer
October 13, 2022
Immunovia nabs CMS preliminary payment determination
By
LabPulse.com staff writers
The CMS preliminary payment determination implied a test price of $897.
September 26, 2022
ACLA campaign, letter seek to stop cuts in lab testing payments
By
Leo O'Connor
ACLA said it is launching a series of digital advertisements as part of its Stop Lab Cuts campaign to urge Congress to pass the Saving Access to Laboratory Services Act.
September 12, 2022
OncoCyte announces evaluation of gene expression test
By
LabPulse.com staff writers
In a clinical trial, 429 patients diagnosed with metastatic urothelial cancer were treated with atezolizumab (Tecentriq, Genentech), an immune checkpoint inhibitor.
August 24, 2022
Labcorp acquires RWJBarnabas Health outreach services
By
LabPulse.com staff writers
With the acquisition, physicians and patients will have access to an expanded test menu, Labcorp's network of patient service centers, expanded health plan coverage, and reduced out-of-pocket lab costs, the organizations said, adding that greater support, service, and same day and STAT testing will be available in rural and local communities.
August 23, 2022
Caris Life Sciences to pay almost $2.9M in false claims lawsuit
By
LabPulse.com staff writers
The Irving, Texas-based company delayed its submission of claims to the Centers for Medicare & Medicaid Services for its predictive biomarker tests, known as Caris Molecular Intelligence and the Adapt Biotargeting System, leading to additional expenses, the DOJ said.
June 1, 2022
AACC lobbies against greater regulation of lab-developed tests
By
Erik L. Ridley
The Verifying Accurate Leading-edge IVCT Development (VALID) Act would limit the availability of laboratory-developed tests, decreasing patient access to these diagnostic tools, the AACC said. Often created when there is no FDA-approved commercial test available, these tests are frequently used to diagnose rare conditions -- such as genetic abnormalities in children -- or to respond to emerging health threats such as COVID-19, according to the association.
May 24, 2022
Lucid promotes new guideline from ACG on esophageal cancer
By
LabPulse.com staff writers
The new guidelines include a reference to screening for esophageal cancer using Lucid's EsoGuard DNA test on samples collected with its EsoCheck Cell Collection device, it said.
April 3, 2022
PGDx receives updated Medicare rate for Elio test
By
LabPulse.com staff writers
The Centers for Medicare & Medicaid Services finalized a national reimbursement rate of $2,919.60 for the proprietary laboratory analyses code (0250U) that PGDx obtained for the test, the company reported in a release.
January 27, 2022
Previous Page
Page 2 of 6
Next Page